RP1 Approved: A Long Road to a New Option for Patients
Thankfully, the third time was the charm! On August 6, 2026 the U.S. Food & Drug Administration (FDA) approved RP1…
08/07/2026
RP1 Approved: A Long Road to a New Option for Patients
Thankfully, the third time was the charm! On August 6, 2026 the U.S. Food & Drug Administration (FDA) approved RP1…
|
08/07/2026
Patient Webinar: Understanding Your Second-Line Options
What the RP1 Approval Means for Patients and the Changing Treatment Landscape For patients with advanced melanoma, hearing that a…
08/06/2026
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
Approval Offers New Hope for Patients with Anti-PD-1 Refractory Melanoma The following is the official press release issued by the…
|
08/06/2026
AIM at Melanoma President Samantha Guild Receives SITC’s 2026 Tara Withington Public Service Award
AIM at Melanoma is proud to announce that our President, Samantha Guild, JD, has been selected as the recipient of…
|
08/03/2026
Back to School Considerations for Sun Safety Knowledge and Behaviors
August is the start of the back-to-school season across the U.S. so now is a good time to provide an…
07/20/2026
More Than a Letter: A Year of Advocacy for Patients with Advanced Melanoma
What does advocacy really mean? For many people, advocacy means raising awareness. For us, it also means showing up where…
|
07/14/2026
Finding Hope, Purpose, and Life Beyond Diagnosis
What does it mean to truly live well after a melanoma diagnosis? In this heartfelt episode of Beyond the Clinic:…
|
|
07/10/2026
Help Bring a New Treatment Option to Patients with Advanced Melanoma
RP1 (vusolimogene oderparepvec ) in combination with nivolumab to treat advanced melanoma is being considered for approval by the FDA…
|
07/06/2026
How Melanoma Changed Adam Harper’s Perspective on Life
Every few months, Adam Harper sits down with a list of goals. Some are ambitious. Others are simple: a trip…
|
06/26/2026
FDA Accepts Review of RP1 for Advanced Melanoma; Decision Expected August 2026
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development…
|
Recent Posts
Aug. 07, 2026
RP1 Approved: A Long Road to a New Option for Patients
Aug. 07, 2026
Patient Webinar: Understanding Your Second-Line Options
Aug. 06, 2026
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
Aug. 06, 2026
AIM at Melanoma President Samantha Guild Receives SITC’s 2026 Tara Withington Public Service Award
Aug. 03, 2026